{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.84","value":"2.976"},{"groupId":"OG001","spread":"27.51","value":"2.231"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"PK parameters of MAAA-1181a\\_Maximum observed concentration","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Final Analysis with DCO on 27Nov2024","id":"OG001","title":"NSCLC Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set:Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.","title":"Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ MAAA-1181a","type":"SECONDARY","unitOfMeasure":"ng/mL"}